admin – Page 5368 – Get News Story

Friedreich’s Ataxia Treatment Market Size in the 7MM will experience significant changes during the forecast period of 2024-2034, estimated DelveInsight

Friedreich’s Ataxia Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Friedreich’s Ataxia Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

DelveInsight’s “Friedreich’s Ataxia Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Friedreich’s Ataxia, historical and forecasted epidemiology as well as the Friedreich’s Ataxia market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Unlock detailed insights into the Friedreich’s Ataxia Market by downloading the comprehensive report from DelveInsight @ Friedreich’s Ataxia Market

Key Takeaways from the Friedreich’s Ataxia Market Report

In September 2024:- PTC Therapeutics- An Open-Label Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Vatiquinone in Children With Friedreich Ataxia Younger Than 7 Years of Age. The primary objective of the study is to assess the pharmacokinetics (PK) and safety of vatiquinone administered in participants with Friedreich ataxia (FA) younger than 7 years.
In September 2024:- Reata- Friedreich’s ataxia is an autosomal recessive cerebellar ataxia caused by triplet-repeat expansions. The causative mutation is a trinucleotide (GAA) repeat expansion in the first intron of the frataxin gene, leading to impaired transcription of frataxin. The pathological consequences of frataxin deficiency include a severe disruption of iron-sulfur cluster biosynthesis, mitochondrial iron overload coupled to cellular iron dysregulation, and an increased sensitivity to oxidative stress.
Based on a secondary research genetically confirmed Friedreich’s ataxia patient has not been found in the Japanese population, and the majority of patients with Friedreich’s ataxia-like phenotype may be confirmed as AOA1, AOA2, ataxia with vitamin E deficiency or autosomal-recessive spastic ataxia of Charlevoix-Saguenay if examined by genetic testing.
According to a study, cases of Friedreich’s ataxia are very rare in Japan. It was observed that among 844 probands with various types of spinocerebellar degeneration reported by approximately 200 major neurological clinics in Japan, there were 26 males and 26 females diagnosed with Friedreich’s ataxia.
As per the statistics by National Institute of Neurological Disorders and Stroke, although rare, Friedreich’s ataxia is the most common form of hereditary ataxia in the United States, affecting about 1 in every 50,000 people. Adult or late-onset Friedreich’s ataxia is less common, <25% of diagnosed individuals, and can occur anytime during adulthood.
According to a study in 2009, Friedreich’s ataxia is the most common of the inherited ataxias across most of Europe. Its prevalence is highest in Western Europe, with more than 1 case per 30,000 individuals (1/30,000) reported in north-west Spain.
The leading Friedreich’s Ataxia Companies such as Neurocrine Biosciences, Takeda, Reata Pharmaceuticals Inc., AbbVie, Minoryx Therapeutics S.L., ApoPharma, Metro International Biotech LLC, PTC Therapeutics, Design Therapeutics Inc., Larimar Therapeutics Inc., Veristat Inc., Retrotope Inc., and others.
Promising Friedreich’s Ataxia Therapies such as Vatiquinone, Omaveloxolone Capsules, 2.5 mg, and others.

Gain a competitive edge in the Friedreich’s Ataxia Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Friedreich’s Ataxia Treatment Drugs

Friedreich’s Ataxia Epidemiology Segmentation in the 7MM

Total Friedreich’s Ataxia Prevalent Cases
Friedreich’s Ataxia Diagnosed Prevalent Cases
Friedreich’s Ataxia Onset Type Diagnosed Prevalent Cases
Friedreich’s Ataxia Age-specific Diagnosed Prevalent cases

Friedreich’s Ataxia Market Insights

Friedreich’s Ataxia is an inherited neurodegenerative disease, for which there is only one US FDA-approved treatment. Treatments for Friedreich’s ataxia have targeted specific symptoms of the disease rather than the underlying cause, and to a greater degree, these therapeutic options still make up the gold standard Friedreich’s ataxia care. There is no cure for the disease, but there are ways to manage the condition and improve the quality of life for those living with Friedreich’s ataxia. Fortunately, the most life-threatening symptom in patients with Friedreich’s ataxia, i.e. Heart disease, can be controlled with treatments developed for use in the general population.

Discover key developments and opportunities in the Friedreich’s Ataxia Market. Click here to learn more from DelveInsight’s latest report @ Friedreich’s Ataxia Market Size

Friedreich’s Ataxia Therapeutics Market Landscape

The Friedreich’s ataxia market in the 7MM (United States, EU4 and the UK, Japan) is poised for growth, driven by increasing awareness of the disease and advancements in genetic testing. Currently, the market is characterized by a limited number of treatment options, with ongoing research and clinical trials exploring novel therapies. The rising prevalnce of Friedreich’s ataxia has led to greater demand for specialized care and support services. Additionally, collaborations between pharmaceutical companies and research institutions are fostering innovation in potential therapies. As awareness continues to grow, the market is expected to attract investment and drive the development of new treatment modalities, ultimately improving patient outcomes.

Friedreich’s Ataxia Treatment Market

The Friedreich’s ataxia treatment market goal primarily focuses on managing symptoms, slowing down the progression of the disease, and improving the quality of life for patients. This often involves a multidisciplinary approach, including physical therapy, occupational therapy, speech therapy, and medications to manage symptoms such as slurred speech, muscle stiffness, loss of reflexes, and fatigue. Additionally, research efforts are ongoing to develop therapies that target the underlying genetic cause of the disease, with the ultimate aim of finding a cure.

Download DelveInsight’s Friedreich’s Ataxia Market report today and stay ahead in this rapidly evolving field. @ Friedreich’s Ataxia Clinical Trials

Scope of the Friedreich’s Ataxia Market Report

Coverage- 7MM
Friedreich’s Ataxia Companies- Neurocrine Biosciences, Takeda, Reata Pharmaceuticals Inc., AbbVie, Minoryx Therapeutics S.L., ApoPharma, Metro International Biotech LLC, PTC Therapeutics, Design Therapeutics Inc., Larimar Therapeutics Inc., Veristat Inc., Retrotope Inc., and others.
Friedreich’s Ataxia Therapies- Vatiquinone, Omaveloxolone Capsules, 2.5 mg, and others.
Friedreich’s Ataxia Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Friedreich’s Ataxia Unmet Needs, KOL’s views, Analyst’s views, Friedreich’s Ataxia Market Access and Reimbursement

Download the report to understand which factors are driving Friedreich’s Ataxia Market Trends @ Friedreich’s Ataxia Market Trends

Table of Content

1: Key Insights

2: Report Introduction

3: Friedreich’s Ataxia Market Overview at a Glance

4: Key Events

5: Epidemiology and Market Methodology

6: Executive Summary of Friedreich’s Ataxia

7: Disease Background and Overview: Friedreich’s Ataxia

8: Epidemiology and Patient Population

9: Patient Journey

10: Marketed Therapies

11: Emerging Therapies

12: Friedreich’s Ataxia: 7 Major Market Analysis

13: Key Opinion Leaders’ Views

14: SWOT Analysis

15: Unmet needs

16: Market Access and Reimbursement

17. Appendix

18: DelveInsight Capabilities

19: Disclaimer

20: About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Friedreich’s Ataxia Treatment Market Size in the 7MM will experience significant changes during the forecast period of 2024-2034, estimated DelveInsight

JEMSU.ai Launches Innovative AI Marketing Tools for Enhanced Digital Marketing Solutions

JEMSU, a leading provider of SEO and digital marketing solutions, has announced the launch of its new AI marketing tools designed to revolutionize the way businesses approach online marketing.

The introduction of these advanced tools marks a significant milestone in the digital marketing industry. By leveraging artificial intelligence, JEMSU.ai aims to help businesses optimize their marketing strategies, improve customer engagement, and increase return on investment.

The new AI marketing tools offer a range of options from Instant SEO checkers to simultaneous chat with the three largest AI chatbots, OpenAI’s ChatGPT, Anthropic’s Claude and Google’s Gemini. These functionalities are designed to streamline marketing processes and provide actionable insights for businesses of all sizes.

“Artificial intelligence is transforming the digital marketing landscape,” said Chris Sams, President of JEMSU.ai. “Our goal is to provide businesses with the tools they need to stay ahead of the curve. With our AI marketing tools, companies can make data-driven decisions and create more effective SEO and digital marketing campaigns.”

One of the key features of JEMSU.ai’s offering is the interactive A.I marketing assistant capability. This feature allows businesses to chat with A.I about their website, and discuss the tailored marketing solutions provided by the A.I marketing tools. This allows marketing managers and small business owners to gain additional insight, ask questions and get instructions on how to implement.

The tailored content generation feature is another highlight of the new tools. It uses AI to create customized marketing content based on website content. This level of relevancy can lead to higher engagement rates and improved customer satisfaction.

For more information about the new AI marketing tools, visit JEMSU.ai.

Industry experts have praised JEMSU.ai’s initiative, noting that AI-driven tools are becoming essential in today’s competitive market. The ability to quickly adapt to changing consumer behaviors and market conditions can provide a significant advantage.

“Businesses that embrace AI technology in their marketing efforts are likely to see substantial growth”. “Tools like those offered by JEMSU.ai can provide valuable solutions and efficiencies that were not possible with traditional methods.”

JEMSU has a long track record of innovation in the SEO and digital marketing space. The company has provided solutions that address the challenges faced by modern businesses. With the launch of these AI marketing tools, JEMSU.ai continues its commitment to helping clients achieve their SEO and marketing goals.

JEMSU offers a variety of resources and support services to help businesses implement and maximize the benefits of the new tools.

As the digital landscape continues to evolve, businesses are seeking ways to stay competitive and connect with their audience effectively. JEMSU.ai’s AI marketing tools provide a comprehensive solution that addresses these needs.

For businesses interested in enhancing their marketing strategies, JEMSU.ai’s new tools offer a promising avenue for growth and innovation.

About JEMSU.ai

JEMSU.ai is a pioneering company specializing in digital marketing solutions. With a focus on innovation and customer success, JEMSU.ai provides a range of services designed to help businesses thrive in the digital age.

Contact Information

For media inquiries or more information about JEMSU.ai’s AI marketing tools, please contact below.

Media Contact
Company Name: JEMSU.ai
Contact Person: Chris
Email: Send Email
Phone: (720) 545-1555
Country: United States
Website: https://jemsu.ai

Timur Bekmambetov to Teach How to Make Screenlife Films in New Book

In his screenlife filmmaking guidebook, Bekmambetov promises you will start making films with nothing more than a computer and a story.

Hollywood filmmaker Timur Bekmambetov, who is currently in post-production on his new movie Mercy with Chris Pratt for Amazon MGM Studios, has made a name for himself in recent years by disrupting the film business with box office hits like Unfriended, Searching, and Missing, all set entirely on a computer screen. He now aims to inspire more filmmakers around the world to adopt his approach with the release of his first guidebook on making screenlife films, a format he pioneered.

In Screenlife: How To Start Making Movies With Nothing But A Computer And A Story, Bekmambetov and other creators of the most successful screenlife films guide you through the entire moviemaking experience, from coming up with an idea and writing a screenplay to shooting, editing, and distributing your screenlife film. Along the way, they unveil challenges, tips, and professional tricks to help you avoid common mistakes and successfully make your first screenlife film, or perhaps your first movie ever.

Screenlife: How To Start Making Movies With Nothing But A Computer And A Story is designed for filmmakers of all levels, from novices with no prior experience to seasoned professionals looking to explore new creative avenues. By focusing on accessible technology and budget-friendly techniques, Bekmambetov empowers readers to craft compelling stories using just their digital devices.

Bekmambetov managed to prove box office success for his unconventional film format. His debut screenlife production, the teen horror film Unfriended, was picked up by Universal and went on to gross more than $65 million against a budget of $1 million. His next screenlife production, Searching, starring John Cho, became a sensation at the Sundance Film Festival, grossing over $75 million. This film also spawned a sequel, Missing, released in 2023, starring Nia Long and Storm Reid, which grossed $48.8 million worldwide and topped the US movie chart on Netflix last summer. Bekmambetov’s only directorial experience in screenlife to date, the journalist thriller Profile, won an Audience Award at the Berlin Film Festival in 2018.

He also proved that screenlife could work across all genres and types of content. In 2018, BuzzFeed released his documentary web series Future History: 1968, which let users experience historical events through the lens of social media and mobile device screens. In 2019, Snapchat released the zombie apocalypse hit series Dead of Night, produced by Bekmambetov and shot in the screenlife format for in-app smartphone-only viewing by Snapchat users. The screenlife filmmaking technique earned Bekmambetov’s production company, Bazelevs, a place in Fast Company’s Top 10 Most Innovative Video Companies in the World in 2021.

The guidebook is part of Bekmambetov’s initiative to popularize screenlife in both established and emerging film markets and build a global community of screenlife filmmakers. He recently announced the launch of the Screenlife Accelerator Program in the UAE, in collaboration with Image Nation Abu Dhabi, to boost digital filmmaking production in one of the fastest-growing content markets in the world.

Available on Amazon: Screenlife: How to Start Making Movies with Nothing but a Computer and a Story: Bekmambetov, Timur, Stepanov, Vasily, Shavlovsky, Konstantin, Kushner, Barry, Zinovkin, Alex: 9781917185264: Amazon.com: Books

About the Author

Timur Bekmambetov is an acclaimed Hollywood filmmaker and producer, known for creating technologically innovative and visually arresting genre films. Bekmambetov has just finished directing the Amazon MGM Studios sci-fi thriller Mercy (set for release in 2025), starring Chris Pratt and Rebecca Ferguson, that he produced with Oscar-winning producer Charles Roven.

Bekmambetov broke out with the fantasy epic Night Watch (2004). His directorial debut in Hollywood was Marc Millar’s comic book adaptation Wanted (2008) which starred Angelina Jolie and James McAvoy. The action film grossed $341 million, earned two Oscar nominations, and was Universal’s highest grossing “R” film at that time. With Tim Burton, Bekmambetov produced the animated feature 9 (2009) and directed and produced Abraham Lincoln: Vampire Hunter (2012).

Bekmambetov is the pioneer of screenlife films in which the action is set from the point of view of smartphone and computer screens as characters utilize their devices that drive the narrative forward. His debut screenlife production – a teen horror pic Unfriended (2015) – was picked up by Universal and went on to gross more than $65 million against a budget of $1 million. His next screenlife production, Searching (2018) starring John Cho, became a sensation at the Sundance Film Festival, grossing over $75 million. This film has also spawned sequel Missing (2023) starring Emmy-winning Storm Reid that grossed $48.8 million and topped Netflix US movie chart. Screenlife films earned Bekmambetov’s US production company Bazelevs a place in Fast Company’s Top 10 Most Innovative video companies in the world in 2021.

Book Name: Screenlife: How to Start Making Movies with Nothing but a Computer and a Story

Author Name:Timur Bekmambetov

ISBN Number: 1917505930

Kindle Version: Click Here

Paperback Version: Click Here

Media Contact
Company Name: Savvy Book Marketing UK
Email: Send Email
Phone: +44-151-808-0701
Country: United Kingdom
Website: https://savvybookmarketing.co.uk/

Holistic Psychotherapist Rita Tojal Empowers the Mind, Body, and Spirit of Her Clients with Transformative One-On-One Psychotherapy

Tojal is helping her clients enrich their lives with practical, holistic guidance that taps into psychology, spirituality, traveling the world, and more

Rita Tojal offers her clients much more than just psychotherapy sessions; instead, she is changing lives with a holistic approach that intricately intertwines psychology, philosophy, spirituality, somatic practices, and travel to focus on elevating the overall well-being of her clients’ minds, bodies, and spirits.

Tojal resides in the picturesque coastal town of Cascais in Portugal. From here, she connects with clients around the world who are seeking expansive psychotherapy. Tojal leads her clients to total self-acceptance through a myriad of methods including one-on-one sessions, courses, retreats, and more. In her one-on-one sessions, Tojal imparts a diverse and unique blend of guidance for her clients that incorporates tenets of psychotherapy, astrology, life mentoring, and more to yield beautiful transformations. She radically changes her clients’ lives for the better through trauma work, attachment theory, somatics, nature connection, Tibetan buddhism, astrology, and mindfulness.

A self-described introvert, is a psychologist and philosopher who teaches her clients to embrace themselves and experience life-changing personal growth. One of the dynamic ways in which Tojal accomplishes this is through NAMKHA Trips, her travel brand that has taken past guests to awe-inspiring destinations including Dharamshala, India; Japan; Tibet; Mustang and Solukhumbu, Nepal; and Bhutan. Tojal’s travel brand was inspired by her own life, in which she spent more than two decades living and exploring the world nomadically. “I see travel as a tool for self-development,” said Tojal.

Tojal currently has two trips for 2025 that people can register for now. One trip will take guests to North and Central Japan in the Spring, and the other will take travelers to Dharamsala, North India.

While she lives in Cascais, her passion for navigating clients along transformational journeys knows no bounds. From virtual one-on-one sessions to retreats and exotic travel, Tojal is leaving no stone unturned on the path to holistic wellness for clients around the world.

Anyone interested in learning about Tojal’s holistic methods can find information and free resources such as gaia meditation, yoga nidra, and more, by visiting https://www.ritatojal.com/.

ABOUT RITA TOJAL

Psychotherapist Rita Tojal guides her clients towards transformation through a blend of tailored psychotherapy, spirituality, somatic practices, nature, travel, and more. Follow Rita on social media:

Instagram: @rita.tojal

Facebook: @ritatojal

Media Contact
Contact Person: Rita Tojal
Email: Send Email
City: CASCAIS
Country: Portugal
Website: https://www.ritatojal.com/

Neurogenic Detrusor Overactivity Treatment Market Size in the 7MM is expected to witness a major change in the study period 2020-2034

Neurogenic Detrusor Overactivity Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Neurogenic Detrusor Overactivity Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

DelveInsight’s “Neurogenic Detrusor Overactivity Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Neurogenic Detrusor Overactivity, historical and forecasted epidemiology as well as the Neurogenic Detrusor Overactivity market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Unlock detailed insights into the Neurogenic Detrusor Overactivity Market by downloading the comprehensive report from DelveInsight @ Neurogenic Detrusor Overactivity Market

Key Takeaways from the Neurogenic Detrusor Overactivity Market Report

The growth of the Neurogenic Detrusor Overactivity Market is expected to be primarily driven by increasing prevalence, increasing awareness, and improved diagnosis along with anticipated approval of emerging therapies.
In September 2024:- Astellas Pharma- A Phase 3, Open Label, Multicenter, Baseline-Controlled Sequential Dose Titration Study Followed by a Fixed Dose Observation Period to Evaluate Pharmacokinetics, Efficacy and Safety of Mirabegron Prolonged-Release Microgranula-Based Suspension in Children From 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity.
In September 2024:- EG 427- First-In-Human Phase 1b/2a Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adult Participants with Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization.
Neurogenic Detrusor Overactivity is estimated to affect 50–90% of patients with multiple sclerosis and 70–84% of patients with SCI.
Neurogenic Detrusor Overactivity in children can be caused by various conditions, including transverse myelitis, spinal cord injury, and spina bifida. Spina bifida is the most common cause, affecting 1,500–2,000 of the over 4 million babies born annually in the US.
It was found that the prevalence of urinary incontinence was 50.9% in patients with MS, 52.3% with SCI, 33.1% with Parkinson’s disease, and 23.6% with stroke.
The prevalence of urinary symptoms in patients with Parkinson’s disease was found to be nearly3% for detrusor hyperreflexia with detrusor-sphincter dyssynergia in Japan.
The prevalence of detrusor hyperreflexia in patients with Parkinson’s disease was found to be approximately 7.7% in Italy.
The leading Neurogenic Detrusor Overactivity Companies such as Astellas Pharma Inc., RECORDATI GROUP, Taris Biomedical LLC, Urovant Sciences GmbH, ethica Clinical Research Inc., Pfizer, GlaxoSmithKline, Ipsen, Allergan, Boehringer Ingelheim, Watson Pharmaceuticals, AbbVie, and others.
Promising Neurogenic Detrusor Overactivity Therapies such as Mirabegron, Vibegron, EG110A, and others.

Gain a competitive edge in the Neurogenic Detrusor Overactivity Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Neurogenic Detrusor Overactivity Treatment Drugs

Neurogenic Detrusor Overactivity Epidemiology Segmentation in the 7MM

Total Neurogenic Detrusor Overactivity Prevalent Cases
Total Neurogenic Detrusor Overactivity Diagnosed Prevalent Cases
Neurogenic Detrusor Overactivity Condition-specific Diagnosed Prevalent Cases
Neurogenic Detrusor Overactivity Treated Cases

Neurogenic Detrusor Overactivity Market Insights

The primary management of NDO focuses on behavioral approaches, such as increasing the frequency of urination, reducing fluid intake in the evening, avoiding diuretics like caffeine and alcohol, and using absorbent undergarments or bed pads. Pharmacologic treatments are the next step in managing NDO. Anticholinergic medications are commonly used, as they reduce detrusor muscle activation by blocking cholinergic muscarinic receptors. These drugs are available in both oral and transdermal forms, but they are nonspecific and can cause systemic side effects such as dry eyes, dry mouth, and visual disturbances due to ciliary muscle paralysis. Gastrointestinal effects like reduced motility and secretion can result in halitosis, dental caries, and constipation. Additionally, anticholinergic therapy may decrease sweating, which can be particularly problematic for multiple sclerosis patients who already experience heat intolerance.

Discover key developments and opportunities in the Neurogenic Detrusor Overactivity Market. Click here to learn more from DelveInsight’s latest report @ Neurogenic Detrusor Overactivity Market Size

Neurogenic Detrusor Overactivity Drugs Uptake

DYSPORT (abobotulinumtoxinA) is an injectable form of a botulinum neurotoxin type A (BoNT-A) product, which is a substance derived from Clostridium bacteria producing BoNT-A that inhibits the effective transmission of nerve impulses and thereby reduces muscular contractions. It is supplied as a lyophilized powder. DYSPORT is approved for the management of urinary incontinence in adults with NDO due to SCI or multiple sclerosis in multiple countries including the UK and others.
BOTOX is a neuromuscular blocking agent and acetylcholine release inhibitor used for managing neurogenic detrusor overactivity (NDO) in pediatric patients aged 5 years and older who do not respond adequately to or are intolerant of anticholinergic medications. It is the first neurotoxin approved specifically for this indication.
MYRBETRIQ (mirabegron extended-release tablets) and MYRBETRIQ S (mirabegron extended-release oral suspension granules) are beta-3 adrenergic agonists indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older in the US. Additionally, mirabegron is marketed under the brand name BETMIGA for the treatment of NDO.

Neurogenic Detrusor Overactivity Emerging Drugs Profile

EG110A: EG 427

EG110A is a recombinant herpes simplex virus type 1 (HSV-1)-derived vector that does not replicate and expresses the light chain of botulinum neurotoxin F (BoNT/F-LC) under the control of the human calcitonin gene-related peptide (hCGRP) promoter. It is designed to provide long-term, sensory neuron-selective transgenic expression in bladder afferents.

Download DelveInsight’s Neurogenic Detrusor Overactivity Market report today and stay ahead in this rapidly evolving field. @ Neurogenic Detrusor Overactivity Clinical Trials

Scope of the Neurogenic Detrusor Overactivity Market Report

Coverage- 7MM
Neurogenic Detrusor Overactivity Companies- Astellas Pharma Inc., RECORDATI GROUP, Taris Biomedical LLC, Urovant Sciences GmbH, ethica Clinical Research Inc., Pfizer, GlaxoSmithKline, Ipsen, Allergan, Boehringer Ingelheim, Watson Pharmaceuticals, AbbVie, and others.
Neurogenic Detrusor Overactivity Therapies- Mirabegron, Vibegron, EG110A, and others.
Neurogenic Detrusor Overactivity Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Neurogenic Detrusor Overactivity Unmet Needs, KOL’s views, Analyst’s views, Neurogenic Detrusor Overactivity Market Access and Reimbursement

Download the report to understand which factors are driving Neurogenic Detrusor Overactivity Market Trends @ Neurogenic Detrusor Overactivity Market Trends

Table of Content

1. Key Insights

2. Executive Summary of Neurogenic Detrusor Overactivity

3. Competitive Intelligence Analysis for Neurogenic Detrusor Overactivity

4. Neurogenic Detrusor Overactivity: Market Overview at a Glance

5. Neurogenic Detrusor Overactivity: Disease Background and Overview

6. Patient Journey

7. Neurogenic Detrusor Overactivity Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Neurogenic Detrusor Overactivity Unmet Needs

10. Key Endpoints of Neurogenic Detrusor Overactivity Treatment

11. Neurogenic Detrusor Overactivity Marketed Products

12. Neurogenic Detrusor Overactivity Emerging Therapies

13. Neurogenic Detrusor Overactivity: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Neurogenic Detrusor Overactivity

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Neurogenic Detrusor Overactivity Treatment Market Size in the 7MM is expected to witness a major change in the study period 2020-2034

New Book Release: Extreme Nazarene: Present Day Saints and Soldiers by Adam P Childress, M.A.O.M.

In a world fraught with spiritual challenges and moral dilemmas, author Adam P Childress, M.A.O.M., releases his groundbreaking new book, Extreme Nazarene: Present Day Saints and Soldiers. This powerful work calls Christians to rise as spiritual warriors, equipped to face the battles of our time with unwavering faith and purpose.

Extreme Nazarene addresses the urgent need for a renewed sense of mission among Christians today. Childress draws on his extensive personal experiences, including his time in the military and his academic background, to offer a unique perspective on how to embody the role of Christ’s soldiers in the modern world. The book guides readers through the process of recognizing their spiritual mission and provides practical advice on how to prepare for and engage in the spiritual warfare that all believers inevitably face.

Childress’s book is more than just a call to arms; it is a comprehensive guide to spiritual resilience. Through a series of insightful chapters, he explores the importance of returning to the basics of the Christian faith, much like soldiers returning to their basic training. By relating the teachings of the Bible to military principles, Extreme Nazarene offers a structured approach to developing a strong spiritual foundation. This foundation, Childress argues, is essential for Christians to effectively communicate the love of Christ in their private lives, professional environments, and public interactions.

Childress also delves into the importance of Christian fellowship and the power of unity among believers. He emphasizes that, just as in any military force, success in spiritual warfare is not achieved in isolation. Rather, it requires a strong sense of community and mutual support among those who share the same faith. His writing encourages readers to build and nurture these connections, reinforcing the idea that Christians are part of the greatest spiritual military ever assembled on Earth.

Extreme Nazarene: Present Day Saints and Soldiers is available now on Amazon and other major book retailers. It is an essential read for anyone seeking to deepen their faith, strengthen their resolve, and stand firm in the face of spiritual opposition. As the world continues to grow more complex and challenging, Childress’s book serves as a timely reminder that, with the right preparation and mindset, every Christian can rise to the occasion as a true soldier of Christ.

About the Author

Born in 1966 in Harvey, Illinois (South Chicago). That very year, my mother, sister, and I were caught in the blizzard of 1966 in Chicago. We would have starved to death if my mother had not used serious survival skills to make pancakes out of flour and water for months. That was a close call. My parents’ marriage was hitting major lows. My father, who spent three tours in Vietnam, was by this time quite a different person altogether. After some brutal encounters, my parents split. What a beginning! We, my older sister and baby brother entered the foster care system.

Later, we were pawned off to a more permanent foster family. Life was not the same in this foster home. After two and a half years of sexual, physical, and mental abuse, we were a mess. While living at the foster home, I learned to work hard and long hours.

In the meantime, our little minds were shutting down, and we ate like animals. We did not use forks, knives, or spoons all the time. We ate with our hands. Some days, we acted totally normal, and other days like a wild pack of dogs. After a time, the state gave us a battery aptitude test to evaluate us. I was certified as mentally retarded. Now, the abuse stepped up a notch. The “retarded boy” did not understand what was going on. (I do want to make something completely clear: the foster parents had nothing to do with the sexual abuse.)

My grandfather, who resided in Italy, had written letters several years later to every state senator and congressman in America. Finally, the battle for the three children began. By 1976, my grandfather, my mother, and her new soon-to-be-husband won the battle. Praise God. Finally, we loaded up in the brand-new Grand Prix they showed up in and headed to Colorado Springs, Colorado. A new family I began to watch days turn into months and then years.

I began to smarten up. I watched as, time after time, my brothers would brutally speak words of hate. They would defy their father and mother. I realized I did not want to cause any more pain, shame, or fear to my family. I stayed out of trouble as best as a curious boy could. I began focusing on how to help myself in this life. I went to church off and on. I was not really committed but interested in the girls, food, and fun. I began mowing grass and washing cars. It kept me busy and out of trouble. It even made my parents happy. I stuttered a little when I spoke and was extremely fearful of having to explain a mistake. I had no confidence in myself.

We were moving again, this time to Las Vegas, Nevada. Seventh grade in Las Vegas was like being sent to prison every school day. I was sure someone was going to kill me just because I was slow to speak. All you had to say was boo, it would have made me pee my pants. Eighth grade was a little different. I guess I started getting better looking. I had a lot of attention from the girls. This made me popular and a target for the local school gangs. Here is where I learned to put my hidden talent to work. I found out that fighting back meant respect. So, I began protecting myself and anyone who could not.

High school quickly approached, and home life sucked big time. Our family had been torn to shreds by everyone’s horrible behavior. My freshman year in high school was smooth. I saw seniors roughing up freshmen all around me, but no one was pushing me around. Maybe I did not look like a freshman. I played football and was on the wrestling team. My sophomore year was just about the same.

I began to work a job full time. In my junior year, I did not go out for football or wrestling. I began to get bored with it. I was barely passing my classes during ninth and tenth grades. The eleventh grade quickly went by. I would party all night long. I went to school and worked a full-time job. After work it was straight to the clubs to drink and dance. Senior year came and parties were nonstop.

The school was a roller coaster ride. I missed so many days the principal threatened to not let me graduate! I had been awarded a scholarship to UNLV for vocal music. Things were looking up. My girlfriend’s parents moved to a nearby town called Pahrump. In Pahrump, I had gotten involved in shady dealings and almost had gotten shot. I never did collect on the scholarship. I soon realized the path I was on was going to lead me straight to the grave or prison. I thought long and hard about my life. I was 18 and a new believer in Jesus Christ. I knew if I did not change my behavior, I would never make it alive. I decided to join the U.S. Army. Joining the Army was one of the best decisions I would ever make. Eventually, I was recruited by a clandestine group and began participating in special intelligence operations. I was privileged to have traveled over sixty countries while serving in United States Army.

Book Name: Extreme Nazarene

Author Name: Adam P Childress, M.A.O.M

ISBN Number: 979-8330252817

Kindle Version: Click Here

Paperback Version: Click Here

Hardcover Version: Click Here

Media Contact
Company Name: Book Publishing Pros
Email: Send Email
Phone: +1-213-734-5715
Address:17595 Harvard Ave, Ste C-641
City: Irvine
State: California
Country: United States
Website: https://bookpublishingpros.co

Greece Data Center Colocation Market to Reach $125 Million by 2029, Greece Attracts Major Cloud Investments, Establishing Itself as a Key Computing Hub – Arizton

“Greece Data Center Colocation Market Research Report”

Get Insights on 15 Existing Colocation Data Center Facilities and 03 Upcoming Facilities across Greece.

According to Arizton’s latest research report, the Greece data center colocation market is growing at a CAGR of 14.32% during 2023-2029.

Looking for More Information? Click: https://www.arizton.com/market-reports/greece-data-center-colocation-market

Report Scope:    

Market Size (Colocation Revenue): USD 125 Million (2029)

Market Size (Utilized White Floor Area): 290 thousand Sq. Ft. (2029)

Market Size (Utilized Racks): 9 thousand Units (2029)

Market Size (Utilized IT Power Capacity): 57 MW (2029)

Base Year: 2023

Forecast Year: 2024-2029

Book the Free Sample Now: https://www.arizton.com/market-reports/greece-data-center-colocation-market

In Greece, colocation operators added over 184,000 square feet of core and shell white floor area, with approximately 80,110 square feet actively utilized, reflecting a utilization rate of more than 40%. According to Turner & Townsend’s Data Center Cost Index, the core and shell development costs for data centers in Athens range from $6.5 to $7.0 per watt, notably lower than costs in other major European markets like Frankfurt, London, Amsterdam, Paris, and Dublin.

Major players in the Greek data center market include Telecom Italia Sparkle, Digital Realty (Lamda Helix), Lancom, and Synapsecom Telecoms, all contributing to the expansion of data center facilities, which is expected to increase the white floor area in the coming years. Additionally, Greece offers four free trade zones—located in Thessaloniki, Piraeus, Heraklion, and Astakos Aitoloakarnanias—providing investors with significant incentives, such as a 100% corporate tax exemption and full customs duty exemption.

Greece Emerges as a Cloud Computing Hub with Major Investments

Since the implementation of Greece’s cloud-first policy in September 2020, the country has attracted top cloud providers like AWS, Microsoft, and Google, enhancing user experience, reducing costs, and positioning Greece as a growing center for cloud computing.

In September 2023, Google Cloud expanded its global infrastructure by launching a new region in Athens, further advancing the nation’s digital capabilities. This moves underscores Google’s commitment to sustainability, with goals to achieve net-zero emissions by 2030.

Additionally, the Greek government is actively promoting cloud investments through initiatives like the Innovation and Entrepreneurship Fund (INNOVATHENS), which provides grants and support to startups and small businesses developing innovative cloud-based solutions.

What’s Included?

Transparent research methodology and insights on the market’s colocation of demand and supply.
Market size is available in terms of utilized white floor area, IT power capacity, and racks.
Market size available in terms of Core & Shell Vs Installed Vs Utilized IT Power Capacity along with the occupancy %.
An assessment and snapshot of the colocation investment regarding core & shell area, power, and rack in Greece and a comparison between Nordic countries.
The study of the existing Greece data center industry landscape and insightful predictions about industry size during the forecast period.
An analysis of the current and future colocation demand in Greece by several industries.
Study on sustainability status in the region
Analysis of current and future cloud operations in the region.
Snapshot of upcoming submarine cables and existing cloud-on-ramps services in the region.
Snapshot of existing and upcoming third-party data center facilities in Greece
- Facilities Covered (Existing): 15
- Facilities Identified (Upcoming): 03
- Coverage: 4+ locations
- Existing vs. Upcoming (White Floor Area)
- Existing vs. Upcoming (IT Load Capacity)
- Data Center Colocation Market in Greece
  - Colocation Market Revenue & Forecast (2023-2029)
  - Retail Colocation Revenue (2023-2029)
  - Retail Colocation Pricing along with Addons
  - An analysis of the latest trends, potential opportunities, growth restraints, and prospects for the Greece data center colocation market.
  - Competitive landscape, including industry share analysis by the colocation operators based on IT power capacity and revenue.
  - The vendor landscape of each existing and upcoming colocation operator is based on the existing/ upcoming count of data centers, white floor area, IT power capacity, and data center location.

The Report Includes:

Colocation Supply (MW, Area, Rack Capacity)
Colocation Demand (MW, Area, Rack Capacity) and by End-User (Cloud/IT, BFSI, .)
Colocation Revenue (Retail & Wholesale Colocation Services)
Competitive Scenario (Share Analysis by Revenue & MW Capacity)

Vendor Landscape

Existing Colocation Operators

CloudRock
Digital Realty (Lamda Hellix)
Friktoria
Hostmein IKE
Telecom Italia Sparkle
Lancom
Synapsecom Telecoms

Looking for Customization According to Your Business Requirement? https://www.arizton.com/customize-report/4507

Key Questions Answered in the Report:    

What is the count of existing and upcoming colocation data center facilities in Greece?

What factors are driving Greece data center colocation market?

How much MW of IT power capacity is likely to be utilized in Greece by 2029?

Check Out Some of the Top Selling Research Reports:  

Greece Data Center Market – Investment Analysis & Growth Opportunities 2024-2029

The Greece data center market will witness cumulative investments of over USD 1.34 billion by 2029, growing at a CAGR of 9.91% during the forecast period. Explore! https://www.arizton.com/market-reports/greece-data-center-market

Sweden Data Center Colocation Market – Supply & Demand Analysis 2024-2029

The Sweden data center colocation market size was valued at USD 210 million in 2023 and is expected to reach USD 525 million by 2029, growing at a CAGR of 16.50% during the forecast period. Explore! https://www.arizton.com/market-reports/sweden-data-center-colocation-market

Why Arizton?                                             

100% Customer Satisfaction                                             

24×7 availability – we are always there when you need us                                             

200+ Fortune 500 Companies trust Arizton’s report                                             

80% of our reports are exclusive and first in the industry                                             

100% more data and analysis                                             

1500+ reports published till date                           

Post-Purchase Benefit                                         

1hr of free analyst discussion                                         
10% off on customization

About Us:                                                                                  

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                                                

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                                                 

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                                                      

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1-312-235-2040/+1 302 469 0707    
Country: United States
Website: https://www.arizton.com/market-reports/greece-data-center-colocation-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Greece Data Center Colocation Market to Reach $125 Million by 2029, Greece Attracts Major Cloud Investments, Establishing Itself as a Key Computing Hub – Arizton

Cell Culture Market Size: Set to Reach USD 46.22 Billion by 2031| SkyQuest Technology

“Cell Culture Market”

Cell Culture Market to Reach $46.22B by 2031, Growing at a Significant CAGR | Top Companies: Becton, Dickinson and Company, Corning Incorporated, Eppendorf

Cell Culture Market is a crucial sector belonging to life sciences and biotechnology. It emphasizes cultivating cells under special controlled conditions for drug development, research, and several therapeutic applications. The market is notably driven by technological advancements and modernizations in cell culture techniques. Moreover, the growing cases of chronic illnesses and mounting demand for personalized medicine are further impacting the growth of the market. This also includes the growth and progress made by regenerative medicine stem cell research. These factors altogether are propelling the cell culture market.

The latest trends in cell culture reflect improvements in research, technology, and its applications. Automation technologies are actively being incorporated in different cell culture processes. Automated systems for cell seeding, media preparation, and monitoring significantly decrease human error, improve efficiency and enhance reproducibility. This ultimately streamlines workflows, reduces labor costs and enhances overall throughput. Besides, cell culture is also being used in the development of organoids. Organoids are reduced or miniaturized, in simpler forms of organs developed from stem cells. They are used in the study of drug responses, disease mechanism, and development of tissues. They facilitate regenerative therapies, personalized medicine by offering models that imitate human organ functioning.

Get a Free Sample Research Report:https://www.skyquestt.com/sample-request/cell-culture-market

Segmental Analysis:

By Product Consumables, Sera, Media, Reagents, Bioreactor Accessories, Instruments, Bioreactors, Cell Culture Vessels, Cell Culture Storage Equipment, Cell Culture Supporting Instruments

By Application Stem Cell Technology, Cancer Research, Drug Screening and Development, Tissue Engineering & Regenerative Medicine, Others

By End User Research Institutes, Pharmaceutical & Biotechnology Companies, Others

By Region North America, U.S., Canada, Mexico, Europe, Germany, UK, Italy, France, Spain, Rest of Europe, Asia-Pacific, Japan, China, India, South Korea, Australia, Rest of Asia-Pacific, LAMEA, Brazil, Saudi Arabia, Rest of LAMEA

Improvements in Single-Cell Analysis to Spur Market Growth in FutureThere have been several advances made in single-cell RNA sequencing, which helps in the study of gene expression at patient-level, enlightening fine details and cell heterogeneity of cellular procedures. This helps in the better understanding of cancer biology, complex tissues, and immune responses and aids in the progress of targeted therapies. The market is also witnessing the development of novel cell culture media. Improved and novel media supplements and formulations improve the viability, growth, and productivity of different types of cells, comprising complex stem and primary cells. Furthermore, research teams can now effectively customize media compositions to certain forms or trial needs. This enhances experimental reproducibility and results. These improvements reflect a wider range of modernizations in cell culture, impacted by the growing need for highly accurate models, personalized medicine, and scalable production systems.

In April 2024, Becton, Dickinson and Company announced the commercial supply of novel cell sorters. These sorters will allow more researchers in wider domains, comprising immunology and cancer research, cell biology, and more to unveil insights not visible previously in conventional cytometry trials.
In February 2023, Corning Life Sciences to present a package of 3D culture technologies, comprising the novel Elplasia® 12K flask and Elplasia plate (soon-to-be-unveiled) with an open-well set-up to enable organoid and spheroid manipulations.
In July 2023, Sartorius recently added cell culture media manufacturing building to its current facility in Yauco. The recently unveiled facility of 21,500 square feet will expand Sartorius’s capacities for cell culture.
In July 2023, Merck declared Euro 23 million investment to increase its production of cell culture media in Lenexa Kansas. This comprises 9,100 square foot m2 of extra production space and re-designed laboratory space. The investment will also create employment for people in Kansas City.

Ask for Customization:https://www.skyquestt.com/speak-with-analyst/cell-culture-market

The report covers the following players:

Becton, Dickinson and Company
Corning Incorporated
Eppendorf
Sartorius AG
Merck KGaA
Lonza Group AG
PromoCell GmbH
Danaher Corporation
Thermo Fisher Scientific
HiMedia Laboratories
Agilent
Eppendorf AG

This report covers the following segments:

A. Product
Consumables
Sera
Media
Reagents
Bioreactor Accessories
Instruments
Bioreactors
Cell Culture Vessels
Cell Culture Storage Equipment
Cell Culture Supporting Instruments
B. Application
Stem Cell Technology
Cancer Research
Drug Screening and Development
Tissue Engineering & Regenerative Medicine
Others
C. End-User
Research Institutes
Pharmaceutical & Biotechnology Companies
Others

View report summary and Table of Contents (TOC):https://www.skyquestt.com/report/cell-culture-market

Development of 3D Culture Models and Organoids to Fuel Better Growth of CellsIn conclusion, the latest trends in cell culture highlight major advancements that are transforming the future of medical research and biotechnology. The major developments comprise the growth of organoids and 3D culture models that deliver precision in simulations of in-vivo conditions. The incorporation of AI and automated systems improves data analysis and efficiency and enhances bioreactor and in-cell culture technologies that aid superior quality and scalable growth of cells.

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/cell-culture-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cell Culture Market Size: Set to Reach USD 46.22 Billion by 2031| SkyQuest Technology

Hepatocellular Carcinoma Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024

DelveInsight’s, “Hepatocellular Carcinoma Pipeline Insight 2024” report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Hepatocellular Carcinoma Research. Learn more about our innovative pipeline today! @ Hepatocellular Carcinoma Pipeline Outlook

Key Takeaways from the Hepatocellular Carcinoma Pipeline Report

In September 2024:- Translational Research in Oncology- A Phase III, Multicenter, Randomized, Open-label Trial to Evaluate the Safety and Efficacy of Systemic Therapy With Regorafenib and Pembrolizumab Versus Locoregional Therapy With Transarterial Chemoembolization or Transarterial Radioembolization, for the First-line Treatment of Intermediate-stage Hepatocellular Carcinoma With Beyond Up-to-7 Criteria
In September 2024:- Hoffmann-La Roche- This is a Phase Ib/II, open-label, multicenter, randomized platform study to evaluate neoadjuvant immunotherapy combinations in participants with resectable HCC. The study is designed with the flexibility to open new treatment arms as new agents become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the participant population.
In September 2024:- Akeso- The goal of phase Ib trial is to evaluate the safety and tolerability of AK112 in combination therapies for the purpose of observing the incidence of dose limit toxicity (DLT) as well as the confirmation of maximum tolerable dose (MTD) in the treatment of advanced hepatocellular carcinoma (HCC), so as to determine the recommended phase 2 dose (RP2D) in the second part of the trial.
DelveInsight’s Hepatocellular Carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment.
The leading Hepatocellular Carcinoma Companies such as Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others
Promising Hepatocellular Carcinoma Therapies such as Pembrolizumab, Tislelizumab, HLX53 (1000mg), Atezolizumab, Bevacizumab, Tiragolumab, Nivolumab and others

Stay informed about the cutting-edge advancements in Hepatocellular Carcinoma Treatments. Download for updates and be a part of the revolution in cancer care @ Hepatocellular Carcinoma Clinical Trials Assessment

Hepatocellular Carcinoma Emerging Drugs

Namodenoson: Can-Fite BioPharma

Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5′- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). The drug had been out-licensed to Chong Kun Dang (CKD) Pharmaceutical in Korea and to CMS in China.for the treatment of Liver Cancer and NASH. A Phase I/II study in hepatocellular carcinoma (HCC) successfully met its primary and secondary endpoints demonstrating initial indications for efficacy of Namodenoson. A global Phase II study treating patients with Namodenoson as a second-line therapy has recently been concluded.

SRF388: Surface Oncology

SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine. IL-27 is an immunosuppressive cytokine involved in resolving T cell mediated inflammation. Recent data points to IL-27 as a master regulator of the expression of co-inhibitory receptors expressed on CD4+ and CD8+ T cells. Elevated levels of IL-27 transcripts and mRNA gene signatures are found in cancer and are associated with poor prognoses. Surface Oncology has identified particular tumor types where IL-27 appears to play an important role in the immunosuppressive tumor microenvironment and may contribute to resistance to treatment with checkpoint inhibitors.

Porustobart: Harbour BioMed

Porustobart (HBM4003) is a fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from mice. By enhancing antibody-dependent cell cytotoxicity (ADCC) killing activity, porustobart has demonstrated significantly improved depletion specific to high CTLA-4 Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug in monotherapy and combo-therapy.

Fisogatinib: CStone Pharmaceuticals

Fisogatinib is an orally available, potent, irreversible inhibitor of FGFR4. Fisogatinib was specifically designed to inhibit FGFR4 with exquisite selectivity, thereby sparing the paralogs FGFR1, FGFR2 and FGFR3 and preventing potential adverse effects. Preclinical data has validated FGFR4 as an oncogenic driver for a subset of patients with advanced HCC. The US Food and Drug Administration has granted orphan drug designation to fisogatinib for the treatment of HCC. Fisogatinib is being investigated in the Phase I/II stage of its development for the treatment of patients with FGFR4-activated HCC.

STP705: Sirnaomics

STP705 is composed of two siRNA oligonucleotides targeting TGF-β1 and COX-2 mRNA respectively and formulated in nanoparticles with a proprietary Histidine-Lysine Co-Polymer (HKP) peptide. Each individual siRNA has demonstrated the ability to inhibit the expression of their target mRNA and combining the two siRNAs produces a synergistic effect that diminishes pro-fibrogenic, pro-inflammatory, and pro-tumorigenic factors. Sirnaomics has completed several pre-clinical studies that demonstrate that inhibition of TGF-β1 and COX-2 and is expected to result in the inhibition of tumor growth and provide an alternative approach for the treatment of various liver cancers. Molecular analyses of the effects of administering the combination demonstrated that the inhibition of these targets had effects on downstream gene products associated with numerous oncology targets.

Learn more about Hepatocellular Carcinoma Drugs opportunities in our groundbreaking Hepatic Tumor Research and development projects @ Hepatocellular Carcinoma Unmet Needs

Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Hepatocellular Carcinoma Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Discover the latest advancements in Hepatocellular Carcinoma Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Hepatocellular Carcinoma Pipeline Report

Coverage- Global
Hepatocellular Carcinoma Companies- Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others
Hepatocellular Carcinoma Therapies- Pembrolizumab, Tislelizumab, HLX53 (1000mg), Atezolizumab, Bevacizumab, Tiragolumab, Nivolumab and others
Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Hepatocellular Carcinoma Pipeline on our website @ Hepatocellular Carcinoma Drugs and Companies

Table of Content

Introduction
Executive Summary
Hepatocellular Carcinoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Hepatocellular Carcinoma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Namodenoson: Can-Fite BioPharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
SRF388: Surface Oncology
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
STP705: Sirnaomics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Hepatocellular Carcinoma Key Companies
Hepatocellular Carcinoma Key Products
Hepatocellular Carcinoma- Unmet Needs
Hepatocellular Carcinoma- Market Drivers and Barriers
Hepatocellular Carcinoma- Future Perspectives and Conclusion
Hepatocellular Carcinoma Analyst Views
Hepatocellular Carcinoma Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hepatocellular Carcinoma Clinical Trials, Pipeline Insights, Treatment Drugs, and Companies 2024

Ogden Deck Depot Named Best Lumber Yard in Ogden, Utah

Ogden Deck Depot Logo

Lumber Yard at Ogden Deck Depot

Ogden, Utah – September 20, 2024 – Ogden Deck Depot is proud to announce its recent recognition as the best lumber yard in Ogden, Utah. This award highlights Ogden Deck Depot’s dedication to providing top-quality lumber yard services and its commitment to serving the local community with the finest deck lumber and building materials. Specializing in high-quality lumber and exceptional customer service, Ogden Deck Depot has become the go-to destination for homeowners, contractors, and builders looking for reliable lumber solutions.

Ogden Deck Depot has earned its reputation by offering a wide range of lumber yard services that cater to the needs of DIY enthusiasts and professional builders alike. Whether you’re working on a custom deck, a home renovation, or a larger construction project, Ogden Deck Depot ensures you have access to the best materials available.

“We are honored to be recognized as the top lumber yard in Ogden,” said the Owner of Ogden Deck Depot. “Our focus has always been on providing our customers with the highest quality lumber, deck lumber, and materials, along with excellent service. This recognition reflects our team’s hard work and dedication to helping our community build and improve their outdoor spaces.”

Comprehensive Lumber Yard Services

Ogden Deck Depot is known for its extensive inventory and range of services, designed to meet the diverse needs of customers. From selecting the right type of lumber for your project to providing guidance on deck construction, the team at Ogden Deck Depot is committed to helping customers achieve their goals.

Their key offerings include:

Deck Lumber: A wide selection of high-quality deck lumber, including pressure-treated wood, cedar, and composite options, ensures durability and style for every deck project.
Framing and Structural Lumber: Premium lumber options for framing and structural needs, ideal for everything from residential construction to commercial projects.
Custom Lumber Orders: Personalized assistance for custom lumber orders to ensure you have the exact materials you need for any project, regardless of size or complexity.
Expert Guidance and Support: The team at Ogden Deck Depot offers knowledgeable advice to help you choose the best materials and lumber for your specific project. Their hands-on support ensures customers can confidently tackle any building task.

“Whether you’re looking for deck lumber or materials for a larger construction project, our team is here to guide you every step of the way,” said the Operations Manager at Ogden Deck Depot. “We understand how important it is to have the right materials, and we are committed to helping our customers succeed in their projects with the best lumber available.”

The Best Lumber for Deck Construction

Ogden Deck Depot specializes in providing deck lumber that meets the highest standards of quality and durability. Their extensive selection includes pressure-treated lumber, composite decking materials, and specialty wood products, ensuring that customers can find the perfect materials for their decks. With a focus on sustainable and long-lasting products, Ogden Deck Depot helps homeowners and contractors create outdoor spaces that are built to last.

Looking to the Future

As Ogden Deck Depot continues to serve as the premier lumber yard in Ogden, the company is dedicated to expanding its offerings and enhancing its customer experience. With plans to introduce new lumber products and services in the coming months, Ogden Deck Depot remains committed to being a trusted resource for all building and deck construction needs in Northern Utah.

To celebrate this recognition, Ogden Deck Depot will be hosting an open house, where customers can explore the lumber yard, meet the team, and take advantage of special promotions on deck lumber and other building materials. The event will feature product demonstrations, expert consultations, and exclusive discounts for attendees.

About Ogden Deck Depot

Ogden Deck Depot has been a trusted provider of lumber and building materials in Ogden, Utah, for years. With a focus on quality, customer satisfaction, and expert support, Ogden Deck Depot has established itself as the leading lumber yard in the region. Offering a comprehensive selection of deck lumber, framing materials, and custom orders, Ogden Deck Depot is the preferred choice for builders and homeowners looking for the best materials for their projects.

For more information, visit https://www.ogdendeckdepot.com/ or contact Ogden Deck Depot at (435) 222-5819 or ogdendecks@gmail.com.

Media Contact
Company Name: Ogden Deck Depot
Contact Person: AJ Van Dugteren
Email: Send Email
Phone: (435) 222-5819
Address:190 W 33rd Street #160
City: Ogden
State: Utah 84401
Country: United States
Website: www.ogdendeckdepot.com/